Embase Enhances Adverse Event Monitoring With Seamless Access Across Biomedical Literature and Regulatory Data

Embase Enhances Adverse Event Monitoring With Seamless Access Across Biomedical Literature and Regulatory Data

With Embase and PharmaPendium, researchers can monitor pre-clinical, clinical and post-market information from a single search - improving pharmacovigilance and risk monitoring
AMSTERDAM, May 27, 2014 /PRNewswire/ --

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced an enhanced risk monitoring and pharmacovigilance solution with Embase, its biomedical database, now seamlessly connecting to PharmaPendium, a source of extensive regulatory data. Embase is the world's most comprehensive international biomedical database that enables tracking and retrieval of valuable drug- and disease-specific information; PharmaPendium aggregates the most extensive drug-related regulatory information that supports critical drug development decisions. Both are part of the Elsevier Life Science Solutions Portfolio.

A single drug search in Embase will provide an overview of key information pertaining to the drug of interest, including a snapshot of pre-clinical, clinical and post-marketing reported adverse events. Embase customers with a subscription to PharmaPendium can also link directly into a wealth of regulatory data including FDA and EMA approval documents from the results of their original search query. Pharmacovigilance workflows are improved with risk monitoring based upon more comprehensive data. Together, the two products support more efficient drug development research and more effective management of post-launch risks.

"Whether working on the development of a new drug or monitoring the safety of an existing drug or device, it's crucial that pharmaceutical companies have access to actionable data that improves risk monitoring and saves valuable time," said Daan de Jong, Director Product Development for Elseiver. "We've linked Embase and PharmaPendium to allow scientists to navigate a vast amount of drug safety data and to easily obtain relevant drug information in a single search. Offering complementary solutions is a significant milestone that augments the value of the Elsevier Life Science Solutions portfolio which enables scientists from diverse disciplines to collaborate, accelerate and achieve better R&D outcomes."

Embase customers were automatically upgraded to a new version on April 30, 2014. In addition to the seamless connection to PharmaPendium, the user experience was improved other additional new Embase enhancements including:

   -- Text-filter export - allows users to export filter data up to a
      2,000-variable limit to easily produce and share crucial lists; for
      example, a complete list of diseases found in combination with a
      particular drug search. Users can also explore potential relationships -
      including those between specific drugs and devices - based on the

   -- Streamlined search forms - users can review all search options without
      scrolling down the page and the newly designed auto-complete function
      offers suggestions for search terms covering drug and disease queries. 

   -- Faster search - speeds have improved even for users who access Embase
      from behind strict company firewalls and proxies. 

Embase and PharmaPendium are part of Elsevier's Life Science Solutions, a portfolio of domain-specific, decision support tools which span the discovery and development workflow and work together to support key research outcomes. The portfolio includes Pathway Studio, ScienceDirect, Scopus, TargetInsights, Reaxys, Reaxys Medicinal Chemistry and QUOSA.

Existing and new customers interested in learning more about Elsevier's pharmacovigilance solutions can request additional information here: http://www.elsevier.com/online-tools/embase/contact-sales.

About Elsevier Life Science Solutions

Elsevier Life Science Solutions is a portfolio of domain-specific decision support tools, including TargetInsights (TM), ScienceDirect, Pathway Studio (R), Reaxys(R), Reaxys(R) Medicinal Chemistry, Embase(TM)and PharmaPendium(R). Designed by scientists for scientists, the tools work together to help you create innovative drug therapies and reduce the time and cost of bringing them to market.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey - and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact

Amy Burnis

Director, Strategic Communications



a.burn[email protected]

SOURCE Elsevier

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.